Skip to main content

Search
News

Kineta, Children’s join in pediatric clinical-trial effort

|

Kineta, Children’s join in pediatric clinical-trial effort

June 12, 2014

http://seattletimes.com/html/businesstechnology/2023824050_kinetachildrensxml.html

 

Source - Seattle Times


Seattle biotechnology company Kineta and Seattle Children’s Research Institute are joining in an effort to improve development and testing of therapies for pediatric autoimmune diseases. Their collaboration, called Alliance for Children’s Therapeutics, will be funded both by philanthropic gifts to the research institute and equity investments in Kineta. Its initial aim is to raise $1.5 million and conduct clinical trials of a Kineta drug in treating childhood-onset lupus nephritis, a spokesman said. Researchers say clinical trials of new drugs typically don’t include children, creating uncertainty about the effects and dosages.

Contact Information for Press

If you have not worked with Seattle Children’s before, please read our press policy before contacting us.

The best way to reach the public relations team is via email at press@seattlechildrens.org. This inbox is monitored seven days a week, during and after business hours, on weekends and on holidays.

Phone: 206-987-4500
(8:30 a.m. to 5:30 p.m. Pacific time, Monday–Friday only)

Note: This contact information is for members of the media only. For general hospital or research questions, please call the hospital switchboard at 206-987-2000.

Latest News

Seattle Children’s studying new ways to treat infant brain injuries
8.21.14 — Q13 Fox

A brain injury is serious for anyone, but for infants they can be devastating. Dr. Dennis Mayock of Seattle Children’s, the ... cont.

Training Physicians for Empathy
8.8.14 — HealthLeaders Media

Improving Clinical Management of Stillbirth is an educational session sponsored by the Global Alliance to Prevent Prematurity ... cont.

Remembering Daniel and the Legacy He Left Behind
8.5.14 — On the Pulse Blog

In my last post about “The Fault in Our Stars,” I made a comment about how most patients live, if not thrive after their ... cont.